Over the past two decades, shortages of generic, injectable medications critical to the lifesaving work of hospitals in the United States have become commonplace. Hospitals now maintain permanent drug shortage response teams that seek alternatives to unavailable drugs, a situation that poses risks to patient care. U.S. nonprofit drug company Civica Rx was created in 2018 to address the problems of:• chronic shortages of essential medicines used in hospitals every day• unpredictable price inflation of essential generic medications due to shortages• predatory pricing for certain medicines, including insulin Civica is building a 140,000 square-foot manufacturing facility in Petersburg, Virginia. This facility is the future home of Civica’s affordable insulin and numerous essential sterile injectable medicines that will be used in hospitals across the U.S. Building out Civica’s essential medicine manufacturing facility is a huge team project, with Civica Rx, CRB, groninger group, and SKAN AG coming together at a pivotal time. The new plant, with CRB leading design and construction, includes two groninger high speed filling lines – one for Ready-to-Use (RTU) syringes and one INTEGRA bulk vial line in cooperation with Swiss isolator manufacturer, SKAN.